Drug Search Results
More Filters [+]

SM-934

Alternative Names: sm-934, sm934, sm 934
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.

Mechanisms of Action: TLR7 Antagonist,TLR9 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: RenJi Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SM-934

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Lupus Erythematosus, Systemic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SM934

P2

Completed

Lupus Erythematosus, Systemic

2023-10-13

Recent News Events